GSK ended development of camlipixant, a P2X3 receptor antagonist bought through its Bellus Health acquisition, after mixed Phase 3 outcomes in adults with refractory chronic cough. While Calm-1 met its primary endpoint at week 12 with statistically significant reductions in 24-hour cough frequency versus placebo, Calm-2 missed key goals at week 24, and a lower 25 mg twice-daily regimen failed in both studies. GSK said limited efficacy makes the drug unlikely to transform patient care and is halting work in refractory chronic cough, while continuing Phase 2 trials in irritable bowel syndrome. Analysts framed the move as a setback to blockbuster hopes tied to the respiratory portfolio. The decision shifts competitive dynamics in chronic cough, with Trevi Therapeutics highlighted as a potential beneficiary from ongoing development of its oral nalbuphine ER approach (Haduvio).